• OPTH share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of OPTH shares has decreased $0.01 since the market last closed. This is a 0.20% drop.

  • Closed at $4.95.

    The stock has since dropped $0.06 in after-hours trading.

Key terms

About OPTH

Optimi Health Corp. functions as an end-to-end GMP manufacturer and supplier of psychedelic substances. It offers formulation, active pharmaceutical ingredients (APIs), and drug product manufacturing from preclinical stages to analysis and commercial distribution and It also offers botanical psilocybin and MDMA. The company was founded on May 27, 2020 and is headquartered in Squamish, Canada.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $39.74M

    A market capitalization up to $300 million places OPTH in the micro-capitalization category.

Key terms

Smart score

Latest OPTH news

Sep 16, 2026 8:25am ET Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder Sep 10, 2026 8:45am ET Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder Sep 08, 2026 8:30am ET Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Aug 14, 2026 4:55pm ET Optimi Health Establishes Discretionary Equity Facility Jun 29, 2026 9:00am ET Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression Jun 10, 2026 9:15am ET Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial Jun 08, 2026 8:00am ET Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development Jun 02, 2026 7:30am ET Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia May 29, 2026 8:30am ET Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia May 26, 2026 7:00am ET Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date May 21, 2026 1:07pm ET Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering May 20, 2026 8:00am ET Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

OPTH Financials

1-year income & revenue

  • Total revenue: $304.91K (1Y), $101.27K (Q3)

    Total Revenue increased 6.43% since last year and increased 39.61% since last quarter.

  • Net income: -$2.65M (1Y), -$1.74M (Q3)

    Net Income increased 40.14% since last year and decreased 49.66% since last quarter.

  • Earnings per share: -$0.83 (1Y), -$0.40 (Q3)

    EPS increased 44.17% since last year and decreased 12.15% since last quarter.

Key terms

OPTH Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

OPTH Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    OPTH's competitors are included in the Process Industries sector and Agricultural Commodities/Milling group

  • Market cap: $39.74M

    A market capitalization up to $300 million places OPTH in the micro-capitalization category.

Key terms